These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38001904)

  • 1. Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature.
    Proietti I; Filippi L; Tolino E; Bernardini N; Svara F; Trovato F; Di Cristofano C; Petrozza V; Bagni O; Vizzaccaro A; Skroza N; Potenza C
    Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001904
    [No Abstract]   [Full Text] [Related]  

  • 2. Basosquamous Carcinoma: Comprehensive Clinical and Histopathological Aspects, Novel Imaging Tools, and Therapeutic Approaches.
    Murgia G; Denaro N; Boggio F; Nazzaro G; Benzecry V; Bortoluzzi P; Passoni E; Garrone O; Marzano A
    Cells; 2023 Nov; 12(23):. PubMed ID: 38067165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports.
    Colombo E; Gurizzan C; Ottini A; Caspani F; Bergamini C; Locati LD; Marchiselli C; Alberti A; Lorini L; Licitra LF; Bossi P; Resteghini C
    Front Oncol; 2023; 13():1111146. PubMed ID: 36925925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.
    Peris K; Fargnoli MC; Kaufmann R; Arenberger P; Bastholt L; Seguin NB; Bataille V; Brochez L; Del Marmol V; Dummer R; Forsea AM; Gaudy-Marqueste C; Harwood CA; Hauschild A; Höller C; Kandolf L; Kellerners-Smeets NWJ; Lallas A; Leiter U; Malvehy J; Marinović B; Mijuskovic Z; Moreno-Ramirez D; Nagore E; Nathan P; Stratigos AJ; Stockfleth E; Tagliaferri L; Trakatelli M; Vieira R; Zalaudek I; Garbe C;
    Eur J Cancer; 2023 Oct; 192():113254. PubMed ID: 37604067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment.
    Dessinioti C; Stratigos AJ
    Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basosquamous cell carcinoma: a survey of 76 patients and a comparative analysis of basal cell carcinomas and squamous cell carcinomas.
    Betti R; Crosti C; Ghiozzi S; Cerri A; Moneghini L; Menni S
    Eur J Dermatol; 2013; 23(1):83-6. PubMed ID: 23238332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-Life Experience with Sonidegib for Locally Advanced Basosquamous Carcinoma: A Case Series.
    Bocchino E; Cappilli S; Palmisano G; Paradisi A; Piccerillo A; Di Stefani A; Peris K
    Case Rep Dermatol; 2024; 16(1):1-7. PubMed ID: 38178864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review.
    Zelin E; Mazzoletti V; Cavallo F; Nardello C; Corio A; Toffoli L; Tagliaferri L; Conforti C; Di Meo N; Zalaudek I
    Australas J Dermatol; 2024 Mar; 65(2):103-113. PubMed ID: 37927116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cemiplimab for locally advanced and metastatic basal cell carcinoma.
    Damsin T; Lebas E; Marchal N; Rorive A; Nikkels AF
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):243-248. PubMed ID: 35175882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
    Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
    Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation.
    Potestio L; Scalvenzi M; Lallas A; Martora F; Guerriero L; Fornaro L; Marano L; Villani A
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current clinical approach to difficult-to-treat basal cell carcinomas.
    Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
    Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete response of advanced cutaneous squamous cell and basal cell carcinomas with sequential cemiplimab and sonidegib therapy.
    Weis J; Grote C; Weichenthal M; Hauschild A
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():66-69. PubMed ID: 34855253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
    Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
    Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again.
    Davis CM; Lewis KD
    Ther Adv Med Oncol; 2022; 14():17588359211066147. PubMed ID: 35082923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary basosquamous carcinoma of the lower eyelid with ocular invasion A case report.
    Papadopoulos GO; Charitonidi E; Filippou N; Fanidou D; Filippou D; Scandalakis P
    Ann Ital Chir; 2018 Mar; 7():. PubMed ID: 29626183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basosquamous carcinoma.
    Bowman PH; Ratz JL; Knoepp TG; Barnes CJ; Finley EM
    Dermatol Surg; 2003 Aug; 29(8):830-2; discussion 833. PubMed ID: 12859383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host immune responses and peritumoral stromal reactions in different basal cell carcinoma subtypes: histopathological comparison of basosquamous carcinoma and high-risk and low-risk basal cell carcinoma subtypes.
    Duman N; Şen Korkmaz N; Erol Z
    Turk J Med Sci; 2016 Jan; 46(1):28-34. PubMed ID: 27511329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and epidemiological analysis of basosquamous carcinoma: results of the multicenter study.
    Ciążyńska M; Sławińska M; Kamińska-Winciorek G; Lange D; Lewandowski B; Reich A; Pabianek M; Szczepaniak K; Hankiewicz A; Ułańska M; Morawiec J; Błasińska-Morawiec M; Morawiec Z; Piekarski J; Brodowski R; Zaryczańska A; Sobjanek M; Owczarek W; Słowińska M; Wróbel K; Bieniek A; Woźniacka A; Skibińska M; Narbutt J; Niemczyk W; Ciążyński K; Lesiak A
    Sci Rep; 2020 Oct; 10(1):18475. PubMed ID: 33116191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.